Angela Lamb, MD: Breaking the Itch-Scratch Cycle in Prurigo Nodularis

April 15, 2026

Angela Lamb, MD, an associate professor of dermatology at the Icahn School of Medicine at Mount Sinai in New York, discusses recent advancements in understanding and treating prurigo nodularis and chronic itch disorders. She highlights the role of interleukin (IL)-31 in driving the itch-scratch cycle. She explains that nemolizumab (Nemluvio) targets the IL-31 receptor, which is expressed on dorsal root ganglion cells, mast cells, basophils, and keratinocytes, helping to disrupt key itch signaling pathways.

Topics Covered:

Understanding pruritus and its impact on patients with prurigo nodularis
Mechanism of action and immunological insights
Efficacy and safety of nemolizumab

MORE EXPERT PERSPECTIVES IN PRURIGO NODULARIS:

David Cotter, MD, PhD: Patient Presentation and Clinical Trial Data for Prurigo Nodularis

David Cotter, MD, PhD, a board-certified dermatologist at Las Vegas Dermatology in Las Vegas, Nevada, discusses a patient case of prurigo nodularis and related trial

Jenny Murase, MD: Assessing Symptoms and Presentation of Patients with Prurigo Nodularis

Dr. Murase discusses the symptoms and presentation of prurigo nodularis and highlights recent research that demonstrates the effectiveness of nemolizumab for treating patients with this

James Del Rosso, DO, and David G. Cotter, MD, PhD: Targeting the IL-31 Neuroimmune Pathway for Treating Prurigo Nodularis

Drs. Del Rosso and Cotter discuss advances in the molecular understanding of prurigo nodularis, which have enabled the development of targeted pharmaceuticals that treat the

Diego Ruiz Dasilva, MD, FAAD: Providing Treatment for Challenging Cases of Chronic Pruritus

Dr. Dasilva discusses a case series that demonstrated the marked efficacy of nemolizumab in patients with treatment-resistant chronic pruritus. Reference: Dasilva D, Soto-González A, Mollanazar

JCAD Archives